ENO3 and hereditary leiomyomatosis and renal cell cancer: The majority of alterations, 18 candidates,were elevated in HLRCC cases and the most abundant included several metabolic regulatory targets, including lactate dehydrogenase (LDHA, + 1.54 LogFC in HLRCC versus NS), glucose transporter 1 (SLC2A1, + 1.06 LogFC), enolase 3 (ENO3, + 0.7 LogFC), succinate dehydrogenase (SDHA, + 0.65 LogFC) as well as proteasome activator complex subunit 1 (PSME1, + 0.67).